Strong Q2 results featured double-digit EPS and EBIT growth, margin expansion, and robust cash flow, prompting an upgrade in full-year EPS guidance to 10%-15%. Growth was broad-based across Kabi, Helios, and MedTech, with biopharma and innovation-led platforms driving performance.Based on Fresenius…
Q2/26 delivered record returns with 14% Core EPS growth and strong margins across segments. Guidance for FY26 was raised, reflecting robust organic revenue growth and improved profitability, while maintaining a strong balance sheet and strategic flexibility.Original document: Fresenius SE & Co. KGa…
Q2 2026 saw strong organic growth, margin expansion, and a 14% rise in Core EPS, prompting upgraded full-year guidance. Both Fresenius Kabi and Helios delivered robust performance, with improved profitability and returns on capital.Original document: Fresenius SE & Co. KGaA [FRE] Earnings Release —…
Fresenius SE & Co. KGaA/ Key word(s): Financing/Strategic Company DecisionFresenius establishes venture fund of more than €200 million to drive healthcare innovation23.07.2026 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Fresenius is further expanding its ac…
